Barclays analyst Geoff Meacham raised his price target for Eli Lilly to $112 and maintains an Overweight rating on the shares. The analyst continues to like Lilly’s positioning in the second half of 2018 and 2019 given its “differentiated growth profile.” Trulicity is poised to continue growth regardless of the REWIND data outcome, Meacham tells investors in a research note titled “Remaining Bullish Ahead of REWIND.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.